BriaCell Announces TSXV Acceptance of Normal Course Issuer Bid

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 22, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announces that the TSX Venture Exchange (the “TSXV”) has accepted the Company’s Notice of Intention to implement a normal …

BriaCell to Present at the Benzinga Healthcare Small Cap Conference September 29-30

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces today that the Company will be presenting at the Benzinga Healthcare Small Cap Conference, which is being held virtually …

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the “Board”) has authorized the Company’s repurchase program whereby the Company may purchase through the …

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Mr. Marc Lustig to the Company’s Board of Directors, effective September 1, 2021. Marc, through his …

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

NEW YORK and VANCOUVER, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces it will be present at the H.C. Wainwright 23rd Annual Global Investment Conference ( www.hcwevents.com/annualconference ). The conference is …

BriaCell to utilize ImaginAb’s CD8 ImmunoPET imaging technology for whole body visualization of tumor-attacking CD8 T cells

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“ BriaCell ” or the “ Company ”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, jointly announces a …

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the open recruitment and enrollment of their collaborative clinical study with Incyte. The Phase I/IIa combination …

BriaCell to Present at Three Upcoming Investor Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present in the …

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th – 15th, 2021

RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving – an investor conference themed around investor education and advocacy begins next week, July 13th – 15th, 2021. More than 50 companies are scheduled to conduct virtual presentations over the three-day period as well as 1×1 meetings with qualified investors throughout the event. John Hope …

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma, and non-small cell lung cancer. Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer, remains on track to enter the clinic in 2021. BERKELEY, Calif. and VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: …

Skip to content